ClinicalTrials.gg
WithdrawnNCT07625306Updated Oct 14, 2026

Lp(a) Lowering Study of Pelacarsen (TQJ230) in Patients in the US With Elevated Lp(a) and Recent ACS (STEMI/NSTEMI) - Lp(a)FRONTIERS PEARL

A Phase 3 interventional study of Pelacarsen and Placebo in Acute Coronary Syndrome (ACS), sponsored by Novartis Pharmaceuticals. Withdrawn. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Why this study was withdrawn
Study terminated by sponsor following the outcome of the Lp(a)HORIZON study (NCT04023552), which did not meet its primary endpoint
Updated Oct 14, 2026Now WithdrawnStart date moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Acute Coronary Syndrome by Novartis — 2 open to participants now, 2 under way, 1 of them phase 3. Acute Coronary Syndrome · Novartis.

Enrollment
11th of 11
0 · median 400
Started
2026
with 1 other
Phase 3
8 of 11
1 open now
Registered
10th of 11
by date

Among the 11 studies in Acute Coronary Syndrome by Novartis, this one is the 11th largest by enrollment, is one of 2 that started in 2026, is one of 8 in phase 3, and was the 10th registered.

Acute Coronary Syndrome

1,491 studies on the registry are indexed under Acute Coronary Syndrome; 273 are open to participants now.

Browse Acute Coronary Syndrome studies →

Open to participants now

2 of the 11 studies in Acute Coronary Syndrome by Novartis are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 196 Acute Coronary Syndrome studies recruiting now, 145 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 79 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Acute Coronary Syndrome by Novartis, or all of them as a file.
02

Study summary

CTQJ230A1US13 is a randomized, double-blind, placebo-controlled, multicenter phase IIIb study designed to evaluate the efficacy, safety, tolerability, and coronary plaque effects of early pelacarsen (TQJ230) initiation in participants with elevated Lp(a) and recent acute coronary syndrome (ACS).

Read the detailed description

This study consists of Lp(a) measurement and additional screening assessments, a double-blind treatment period of 18 months, and a 16-week safety follow up period from the last dose. Efficacy, safety, and tolerability of pelacarsen (TQJ230) compared to placebo will be assessed throughout the study, with primary analysis at Day 180 and final analysis at Day 540.

03

Conditions studied

  • Acute Coronary Syndrome (ACS)

Keywords

  • Lipoprotein(a)
  • ASCVD
  • Acute Coronary Syndrome (ACS)
  • STEMI
  • NSTEMI
  • pelacarsen (TQJ230)
04

Who can participate

Ages eligible
18 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Lp(a) ≥ 150 nmol/L
  • Within 10 days of hospitalization for ACS event and meets all of the following criteria:
  • Clinical syndrome consistent with spontaneous cardiac ischemia
  • Diagnosis of ACS: ST-elevation myocardial infarction (STEMI) or non-ST-elevation myocardial infarction (NSTEMI)

Exclusion criteria

Exclusion Criteria:

  • Uncontrolled hypertension
  • Heart failure (NYHA) class IV
  • History of of any organs
  • History of hemorrhagic stroke or other major bleeding
  • count ≤ LLN
  • Active liver disease or hepatic dysfunction
  • Significant kidney disease
  • for CCTA or severe contrast allergy
  • Pregnant or nursing women

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Pelacarsen

    Pelacarsen (TQJ230) 80 mg s.c. QM

    Drug: Pelacarsen

  • Placebo comparator
    Placebo

    Corresponding placebo s.c. QM

    Drug: Placebo

Interventions

  • Pelacarsen 80 mg subcutaneously (s.c.) once a month (QM)

    Also known as: TQJ230

  • DrugPlacebo

    Placebo subcutaneously (s.c.) once a month (QM)

06

What researchers measure

Primary outcomes

  1. Change in log-transformed Lp(a) concentration

    Change in log-transformed Lipoprotein A (Lp(a)) concentration from baseline to Day 180

    Time frame: Baseline, Day 180

Secondary outcomes

  1. Proportion of participants with Lp(a) < 105 nmol/L

    Proportion of participants with Lipoprotein A (Lp(a)) \< 105 nmol/L

    Time frame: Day 180 and Day 540

  2. Proportion of participants with TEAEs, TESAEs,TEAEs or TESAEs leading to study drug discontinuation and TEAEs of special interest

    Proportion of participants with: * Treatment-emergent adverse events (TEAEs) * Treatment-emergent serious adverse events (TESAEs) * TEAEs or TESAEs leading to study drug discontinuation * TEAEs of special interest

    Time frame: 22 months

  3. Summary of observed values for Glomerular Filtration Rate (GFR)

    Summary of observed values in GFR (Safety laboratory parameters)

    Time frame: Up to 18 months

  4. Change from baseline in Glomerular Filtration Rate (GFR)

    Change from baseline in GFR (Safety laboratory parameters)

    Time frame: Baseline and up to 18 months

  5. Summary of observed values for Heart Rate (HR)

    Summary of observed values for HR (electrocardiogram)

    Time frame: Up to 18 months

  6. Change from baseline in Heart Rate (HR)

    Change from baseline in HR (electrocardiogram)

    Time frame: Baseline and up to 18 months

  7. Summary of observed values for Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)

    Summary of observed values for SBP and DBP (vital signs)

    Time frame: Up to 18 months

  8. Change from baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)

    Change from baseline in SBP and DBP (vital signs)

    Time frame: Baseline and up to 18 months

  9. Change from baseline to Day 540 in non-calcified coronary plaque volume

    Change from baseline to Day 540 in non-calcified coronary plaque volume, as assessed by CCTA

    Time frame: Baseline and Day 540

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Sep 2026 (actual). Primary completion is estimated for Jan 2029, 28 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 14, 2026: start Aug 2026 → Sep 2026, primary completion Dec 2028 → Jan 2029 and completion Dec 2028 → Jan 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2026
First posted
Jun 4, 2026
StartActual
Sep 1, 2026was Aug 2026
Primary completionEst.
Jan 22, 2029was Dec 2028
CompletionEst.
Jan 22, 2029was Dec 2028
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Withdrawn Study terminated by sponsor following the outcome of the Lp(a)HORIZON study (NCT04023552), which did not meet its primary endpoint
changed Oct 14, 2026
Start date
Aug 31, 2026→Sep 1, 2026 (actual)
Oct 14, 2026
Primary completion
Dec 7, 2028→Jan 22, 2029
Oct 14, 2026
Study completion
Dec 7, 2028→Jan 22, 2029
Oct 14, 2026
Enrollment
240 (estimated)→0 (actual)
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    Not yet recruiting→Withdrawn
    Why stopped Study terminated by sponsor following the outcome of the Lp(a)HORIZON study (NCT04023552), which did not meet its primary endpoint
    Start date Aug 31, 2026→Sep 1, 2026 (now actual)
    Primary completion Dec 7, 2028→Jan 22, 2029
    Study completion Dec 7, 2028→Jan 22, 2029
    Enrollment 240 (estimated)→0 (actual)
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07625306
Responsible party
Sponsor
First posted
Jun 4, 2026
Start date
Sep 1, 2026
Primary completion
Jan 22, 2029 (estimated)
Completion
Jan 22, 2029 (estimated)
Last update
Oct 14, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pelacarsen

Start the discussion